- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.01. | AEON Biopharma Completes BPD Type 2a Meeting With FDA | - | RTTNews | ||
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 21.01. | Aeon Biopharma: Aktie gibt nach FDA-Gespräch und Umschuldung nach | 1 | Investing.com Deutsch | ||
| 21.01. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | AEON Biopharma Inc: AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions | 578 | GlobeNewswire (Europe) | - AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today... ► Artikel lesen | |
| 12.01. | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.25 | AEON Biopharma Inc: AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 1 | GlobeNewswire (USA) | ||
| 15.12.25 | AEON Biopharma announces execution of exchange agreement with Daewoong Pharmaceutical | 1 | Seeking Alpha | ||
| 15.12.25 | AEON Biopharma Inc: AEON Biopharma Announces Execution of Exchange Agreement with Daewoong | 602 | GlobeNewswire (Europe) | - AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise... ► Artikel lesen | |
| 15.12.25 | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.12.25 | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.11.25 | AEON Biopharma Inc: AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling | 773 | GlobeNewswire (Europe) | - First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON"... ► Artikel lesen | |
| 14.11.25 | AEON Biopharma GAAP EPS of -$0.39 | 2 | Seeking Alpha | ||
| 14.11.25 | AEON Biopharma schedules FDA meeting to review botox biosimilar data | 4 | Investing.com | ||
| 14.11.25 | AEON Biopharma Inc: AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth | 582 | GlobeNewswire (Europe) | - FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data - - Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing... ► Artikel lesen | |
| 14.11.25 | AEON Biopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.25 | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.09.25 | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.05.25 | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 259 | GlobeNewswire (Europe) | IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 14.05.25 | AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | 242 | GlobeNewswire (Europe) | - Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen | |
| 25.04.25 | AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance | 788 | GlobeNewswire (Europe) | IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MAINZ BIOMED | 0,767 | +2,57 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| TEMPUS AI | 44,800 | -0,88 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| ABIVAX | 97,80 | -4,86 % | 2 Reasons Abivax Stock Could 10X by 2036 | ||
| ALTERITY THERAPEUTICS | 0,002 | -60,00 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments | ||
| APTEVO THERAPEUTICS | 7,140 | 0,00 % | Aptevo Therapeutics: Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth | Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,340 | +2,64 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,05 | +0,22 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | -1,38 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| BEAM THERAPEUTICS | 28,690 | +0,74 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| QIAGEN | 41,295 | -0,23 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,420 | -0,98 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ARCUTIS BIOTHERAPEUTICS | 24,760 | -8,25 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was... ► Artikel lesen | |
| ERASCA | 14,530 | +6,45 % | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,630 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,580 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan |
AEON BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -6,14 % bei einem Aktienkurs von 1,070 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.